ArticlePathology oncology research : POR2021
Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer.
Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Unveiling the role of RAC3 in the growth and invasion of cisplatin-resistant bladder cancer cells.Journal of cellular and molecular medicine · 2024Article
- Early diagnosis and prognostic potential of RAC3 in bladder tumor.International urology and nephrology · 2024Article
- Machine learning-based on cytotoxic T lymphocyte evasion gene develops a novel signature to predict prognosis and immunotherapy responses for kidney renal clear cell carcinoma patients.Frontiers in immunology · 2023Article
- Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via METTL3-mediated RAC3 mInternational journal of biological sciences · 2023Article
- Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.International journal of molecular sciences · 2022Article
- Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.Frontiers in immunology · 2022Article
- m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.